N@N

Proteonomix, Inc.: Proteonomix, Inc. (PROT) Announces the Appointment of Clifford Miller, Chief Executive Officer of Andrew Mar

^{Published on 2009-01-27 11:04:21, Last Modified on 2009-01-27 11:05:07 - Market Wire}
 

MOUNTAINSIDE, NJ--(Marketwire - January 27, 2009) - Proteonomix, Inc. (PINKSHEETS: [ PROT ]) announces the appointment of Clifford Miller as cosmetic packaging and marketing consultant for its subsidiary, Proteoderm, Inc.

Mr. Miller is a principal and chief executive officer of [ Andrew Martin Company ], a leading developer of contract packaging and sampling for pharmaceuticals and cosmetics. Its capabilities include:

 -- manufacturing: in-house tube manufacturing for pouches, "pillow paks" (packs formed from thin wall medical grade PVC tubing and electronically sealed at intervals) and tubes; -- printing: complete line of printing capabilities to create the packaging design of customers' choice; and -- contract packaging: fully integrated manufacturing facilities. 

The consulting agreement with Mr. Miller also includes a right of first refusal to Andrew Martin Company to provide design, packaging and fulfillment services for Proteoderm's products.

Cliff Miller stated: "I am pleased to lend my 17 years of experience at Andrew Martin Company to the design and manufacture of packaging for [ Proteoderm ] to ensure that the quality of the packaging equals the quality of the product. I believe that Proteoderm's concept of marketing its cosmoceutical products directly to [ dermatologists ], [ plastic surgeons ] and other health care professionals is unique and effective."

Michael Cohen, CEO of Proteonomix, stated: "We welcome Cliff as a consultant to Proteoderm. As the chief executive officer of Andrew Martin Company, he can create a look for our Proteoderm cosmoceuticals, which contain our patent-pending protein matrix, to match their anti-aging capabilities."

About Proteonomix, Inc.

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, has developed a line of anti-aging cosmetics. For more information, please visit [ www.proteonomix.com ], [ www.proteoderm.com ] and [ www.pinksheets.com ].

"Safe Harbor Statement"

Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.